Skip to main content
. 2023 Jan 10;11(1):173. doi: 10.3390/biomedicines11010173

Figure 3.

Figure 3

The expression of various markers on Treg. (A) The interaction of inhibitory immune checkpoints with their ligands impairs the antitumor activity of Treg and enhances the suppressor function of Treg and promotes cancer development. (B) Targeting inhibitory immune checkpoints with monoclonal antibodies (mAbs) as a potential targeted therapy in cancer treatment to inhibit cancer progression. PLZ: Pembrolizumab, NV: Nivolumab: TML: Tremelizumab.